2-Chloro-5h,6h,7h-cyclopenta[d]pyrimidin-4-amine, 95%, 100mg

4-[(3,4-dichlorobenzyl)oxy]benzaldehyde, 95.0%, 250mg

4-Bromo-N-(4-iodophenyl)benzenesulfonamide, 95%, 500mg

[1,2,4]Triazolo[4,3-a]pyridine-7-carbonitrile, 98%, 1g

Benzyl phenyl sulfide, 99.0%, 10g

1-(piperidine-4-carbonyl)piperidine-4-carbonitrile hydrochloride, 95.0%, 250mg

N-(4-AMINOBUTYL)ACETAMIDE HCL, 95%, 250mg

1-Butyl-5-oxo-pyrrolidine-3-carboxylic acid methyl ester, 95.0%, 10g

Señales de obligación probadas en la práctica, 100 mm, 1 pieza

6-Chloro-4-hydroxyquinolin-2(1H)-one, 95.0%, 250mg

2-(3-hydroxyphenyl)-1,4-dihydroquinazolin-4-one, 98%, 250mg

[(2R,3S,4R,5R)-5-(4-Benzamido-2-oxo-1,2-dihydropyrimidin-1-yl)-3-(benzoyloxy)-4-fluoro-4-methyloxolan-2-yl]methyl benzoate, 98%, 500mg

Monohidrato de ácido orótico, mínimo 99%, 50 g, envase de plástico.